Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) News
Latest headlines that mention KNSA, newest first · each headline opens the original publisher
- Last price
- $72.98
- Day change
- -4.89%
- Next earnings
- 2026-10-27 BMO
KNSA headlines
latest coverageBoosted by its exclusive agreement with Regeneron, Kiniksa Pharmaceuticals stands among the top biotech stocks to watch. The post Biotech Stocks To Watch: Regeneron Partner Has Breakout In Sight appeared first on Investor's Business Daily .
Biotech leader Kiniksa stock is poised to hit a fresh buy point after shares soared 25% in response to better-than-expected sales numbers. The post Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat appeared first on Investor's Business Daily .
Sales of Kiniksa Pharmaceuticals' biggest product, Arcalyst, are expected to begin declining in 2030. But the company has a plan. The post Kiniksa's Sales Are Expected To Decline — Why That's All According To Plan appeared first on Investor's Business Daily .
Biotech firm Kiniska is a standout with its profitability. The biotech stock is moving toward a buy zone amid a winning streak. The post Biotech Kiniksa Pushes Toward A Buy Zone With Blockbuster Drug Sales In View appeared first on Investor's Business Daily .
Image source: The Motley Fool. Tuesday, April 28, 2026 at 8:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading
Also mentioned with KNSA
30d
Headlines that tag both tickers
KNSA news alerts
Get an alert by email or push when a new headline mentions KNSA.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.